FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015685909> ?p ?o ?g. }

• W2015685909 endingPage "474" @default.
• W2015685909 startingPage "464" @default.
• W2015685909 abstract "Background Pentoxifylline potently inhibits cell proliferation, inflammation, and extracellular matrix accumulation. Human studies have proved its antiproteinuric effect in patients with glomerular diseases. Its benefit in addition to angiotensin receptor blockade in patients with chronic kidney disease is not clear. Study Design Randomized controlled study. Setting & Participants 85 patients with estimated glomerular filtration rate (eGFR) of 10 to 60 mL/min/1.73 m2 and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital. Intervention In the first stage (12 months), group 1 served as control and group 2 was administered pentoxifylline. In the second stage (6 months), both groups were administered pentoxifylline. The pentoxifylline dose was 400 mg twice daily for patients with eGFR of 30 to 60 mL/min/1.73 m2 or once daily for patients with eGFR of 10 to 29 mL/min/1.73 m2. Outcomes Proteinuria and eGFR. Measurements Proteinuria was assessed as total protein-creatinine ratio, eGFR was computed by using the Modification of Diet in Renal Disease Study equation. Results 27 and 29 patients were randomly assigned to groups 1 and 2, respectively. In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, −23.9%) compared with 1,410 to 1,810 mg/g (median change, 13.8%) in the control group. The difference between groups was 38.7% (95% confidence interval, 25.7 to 51.6; P < 0.001). The change in proteinuria was related to the change in urinary tumor necrosis factor α and monocyte chemoattractant protein 1 excretion (R = 0.64 and R = 0.55, respectively; P < 0.001 for both). In the second stage, pentoxifylline reproduced the change in proteinuria in group 1. Limitations Small sample size, disease of late stages, open-labeled study. Conclusions Pentoxifylline added to losartan therapy for 1 year decreased proteinuria in patients with CKD stages 3 to 5. A large-scale clinical trial is necessary to confirm this result. Pentoxifylline potently inhibits cell proliferation, inflammation, and extracellular matrix accumulation. Human studies have proved its antiproteinuric effect in patients with glomerular diseases. Its benefit in addition to angiotensin receptor blockade in patients with chronic kidney disease is not clear. Randomized controlled study. 85 patients with estimated glomerular filtration rate (eGFR) of 10 to 60 mL/min/1.73 m2 and proteinuria with protein greater than 500 mg/g of creatinine on treatment with losartan, 100 mg/d, for longer than 6 months were screened in National Taiwan University Hospital. In the first stage (12 months), group 1 served as control and group 2 was administered pentoxifylline. In the second stage (6 months), both groups were administered pentoxifylline. The pentoxifylline dose was 400 mg twice daily for patients with eGFR of 30 to 60 mL/min/1.73 m2 or once daily for patients with eGFR of 10 to 29 mL/min/1.73 m2. Proteinuria and eGFR. Proteinuria was assessed as total protein-creatinine ratio, eGFR was computed by using the Modification of Diet in Renal Disease Study equation. 27 and 29 patients were randomly assigned to groups 1 and 2, respectively. In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, −23.9%) compared with 1,410 to 1,810 mg/g (median change, 13.8%) in the control group. The difference between groups was 38.7% (95% confidence interval, 25.7 to 51.6; P < 0.001). The change in proteinuria was related to the change in urinary tumor necrosis factor α and monocyte chemoattractant protein 1 excretion (R = 0.64 and R = 0.55, respectively; P < 0.001 for both). In the second stage, pentoxifylline reproduced the change in proteinuria in group 1. Small sample size, disease of late stages, open-labeled study. Pentoxifylline added to losartan therapy for 1 year decreased proteinuria in patients with CKD stages 3 to 5. A large-scale clinical trial is necessary to confirm this result." @default.
• W2015685909 created "2016-06-24" @default.
• W2015685909 creator A5026679342 @default.
• W2015685909 creator A5054129692 @default.
• W2015685909 creator A5061973328 @default.
• W2015685909 creator A5078042249 @default.
• W2015685909 creator A5078946821 @default.
• W2015685909 date "2008-09-01" @default.
• W2015685909 modified "2023-09-26" @default.
• W2015685909 title "Effect of Pentoxifylline in Addition to Losartan on Proteinuria and GFR in CKD: A 12-Month Randomized Trial" @default.
• W2015685909 cites W1968446955 @default.
• W2015685909 cites W1984261234 @default.
• W2015685909 cites W1992234212 @default.
• W2015685909 cites W1993345123 @default.
• W2015685909 cites W1994798389 @default.
• W2015685909 cites W1999316094 @default.
• W2015685909 cites W2002452091 @default.
• W2015685909 cites W2003332051 @default.
• W2015685909 cites W2013511631 @default.
• W2015685909 cites W2015646101 @default.
• W2015685909 cites W2020811647 @default.
• W2015685909 cites W2029405758 @default.
• W2015685909 cites W2044773944 @default.
• W2015685909 cites W2044790611 @default.
• W2015685909 cites W2050319263 @default.
• W2015685909 cites W2055864845 @default.
• W2015685909 cites W2056976690 @default.
• W2015685909 cites W2063270035 @default.
• W2015685909 cites W2072543770 @default.
• W2015685909 cites W2084306201 @default.
• W2015685909 cites W2084343172 @default.
• W2015685909 cites W2090714091 @default.
• W2015685909 cites W2102512302 @default.
• W2015685909 cites W2108140227 @default.
• W2015685909 cites W2108554136 @default.
• W2015685909 cites W2108558127 @default.
• W2015685909 cites W2116111001 @default.
• W2015685909 cites W2118932957 @default.
• W2015685909 cites W2129272088 @default.
• W2015685909 cites W2143144750 @default.
• W2015685909 cites W2153549777 @default.
• W2015685909 cites W2154939734 @default.
• W2015685909 cites W2156632978 @default.
• W2015685909 cites W2166329792 @default.
• W2015685909 cites W2167017890 @default.
• W2015685909 cites W2241455767 @default.
• W2015685909 cites W2615684303 @default.
• W2015685909 doi "https://doi.org/10.1053/j.ajkd.2008.05.012" @default.
• W2015685909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18617301" @default.
• W2015685909 hasPublicationYear "2008" @default.
• W2015685909 type Work @default.
• W2015685909 sameAs 2015685909 @default.
• W2015685909 citedByCount "63" @default.
• W2015685909 countsByYear W20156859092012 @default.
• W2015685909 countsByYear W20156859092013 @default.
• W2015685909 countsByYear W20156859092014 @default.
• W2015685909 countsByYear W20156859092015 @default.
• W2015685909 countsByYear W20156859092016 @default.
• W2015685909 countsByYear W20156859092017 @default.
• W2015685909 countsByYear W20156859092018 @default.
• W2015685909 countsByYear W20156859092019 @default.
• W2015685909 countsByYear W20156859092020 @default.
• W2015685909 countsByYear W20156859092021 @default.
• W2015685909 countsByYear W20156859092022 @default.
• W2015685909 countsByYear W20156859092023 @default.
• W2015685909 crossrefType "journal-article" @default.
• W2015685909 hasAuthorship W2015685909A5026679342 @default.
• W2015685909 hasAuthorship W2015685909A5054129692 @default.
• W2015685909 hasAuthorship W2015685909A5061973328 @default.
• W2015685909 hasAuthorship W2015685909A5078042249 @default.
• W2015685909 hasAuthorship W2015685909A5078946821 @default.
• W2015685909 hasConcept C126322002 @default.
• W2015685909 hasConcept C126894567 @default.
• W2015685909 hasConcept C134018914 @default.
• W2015685909 hasConcept C159641895 @default.
• W2015685909 hasConcept C168563851 @default.
• W2015685909 hasConcept C2778653478 @default.
• W2015685909 hasConcept C2779561371 @default.
• W2015685909 hasConcept C2780091579 @default.
• W2015685909 hasConcept C2780288358 @default.
• W2015685909 hasConcept C2780306776 @default.
• W2015685909 hasConcept C2780404050 @default.
• W2015685909 hasConcept C2908929049 @default.
• W2015685909 hasConcept C71924100 @default.
• W2015685909 hasConcept C84393581 @default.
• W2015685909 hasConcept C90924648 @default.
• W2015685909 hasConceptScore W2015685909C126322002 @default.
• W2015685909 hasConceptScore W2015685909C126894567 @default.
• W2015685909 hasConceptScore W2015685909C134018914 @default.
• W2015685909 hasConceptScore W2015685909C159641895 @default.
• W2015685909 hasConceptScore W2015685909C168563851 @default.
• W2015685909 hasConceptScore W2015685909C2778653478 @default.
• W2015685909 hasConceptScore W2015685909C2779561371 @default.
• W2015685909 hasConceptScore W2015685909C2780091579 @default.
• W2015685909 hasConceptScore W2015685909C2780288358 @default.
• W2015685909 hasConceptScore W2015685909C2780306776 @default.
• W2015685909 hasConceptScore W2015685909C2780404050 @default.
• W2015685909 hasConceptScore W2015685909C2908929049 @default.

• next